"versionIdentifier","rationale","uuid:ID","id","instanceType"
"2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","7e0ba3d7-6af2-40e0-a2c1-22abc1e6bbe0","StudyVersion_1","StudyVersion"
